Clinical Trial Update: Assessment of the Safety of SAR342434 and Humalog® When Administered as Continuous Subcutaneous Insulin Infusion [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating the safety of co-administering SAR342434 with Humalog (insulin lispro) via continuous subcutaneous insulin infusion in adults with Ty…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Drugs mentioned

• Humalog (insulin lispro)
• SAR342434

Snippet

Sponsor: Sanofi | Conditions: Type 1 Diabetes Mellitus | Phase 1 | Status: COMPLETED